Compare AES Corp (AES) vs ARK Genomic Revolution ETF (ARKG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AES Corp vs ARK Genomic Revolution ETF — how do they compare? AES Corp trades at $14.65 (market cap $10.43B), while ARK Genomic Revolution ETF trades at $41.54. The key difference: AES Corp pays a 4.81% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, AES Corp nearer its low. Which is the better fit depends on your goals.
| AES | ARKG | |
|---|---|---|
Market Cap | $10.43B | — |
Sector | Utilities | Sector/Thematic |
52-Week High | $17.28 | $43.57 |
52-Week Low | $11.07 | $23.09 |
Enterprise Value | $39.77B | — |
Dividend Yield | 4.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AES trades at $14.62, up 0.27% on the day, with strong fundamentals including a P/E of 7.59 and net income margin of 10.82%. Recent quarters show consistent earnings beats, while technical indicators signal bearish momentum. The company's pending $33.4 billion acquisition by a BlackRock/EQT consortium, approved by stockholders on June 26, 2026, caps near-term upside at $15 per share but provides a stable exit pathway.
The investment case hinges on the acquisition closing, offering a 2.6% gain to the $15 buyout price plus dividend yield. Risks include deal completion uncertainty and shareholder litigation. With no sell-side analysts recommending sell, the stock presents a low-risk arbitrage opportunity with defined upside and limited downside if the transaction proceeds as planned.
ARKG trades at $43.57, up 1.54% today, with strong technical momentum as moving averages signal bullish sentiment. The ETF benefits from positive biotech sector trends including FDA friendliness and M&A activity. However, key oscillators show neutral readings with RSI indicators suggesting overbought conditions near the $45 resistance level.
The biotech ETF outlook remains favorable amid sector strength, though elevated RSI levels indicate potential near-term consolidation. Investment opportunity lies in continued sector momentum, while risks include market volatility and selective investor sentiment toward biotech companies as noted by JPMorgan bankers in June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AES Corp
AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.
Read more on AES →About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →
